UnknownPhase 2

MTX and Steroid for III-IV aGVHD Treatment

China30 participantsStarted 2021-04-21

Plain-language summary

The aim of the study is to identify the efficacy and safety of methotrexate (MTX) combined corticosteroid treatment for grade III-IV acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Who can participate

Age range15 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients who are fully informed and sign informed consent by themselves or their guardians;
✓. Patients receiving allogeneic hematopoietic stem cell transplantation;
✓. Patients with acute graft-versus-host disease of grade III-IV were diagnosed after transplantation;
✓. Patients with stable implantation of granulocytes and platelets.

Exclusion criteria

✕. Patients who have received more than one transplant;
✕. Patients with overlap syndrome;
✕. Patients within six months after the failure of the first transplantation;
✕. Patients with uncontrollable active infection;
✕. Patients with recurrence of primary malignant hematopathy;
✕. Patients with donor lymphocyte infusion induced graft-versus-host disease after first intervention;
✕. Patients with serious respiratory diseases;
✕. Patients with severe renal insufficiency;

What they're measuring

Overall response rate (ORR) for GVHD treatment after treatment

Timeframe: 14 days

Trial details

NCT IDNCT04958538

SponsorPeking University People's Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-12-31

Contact for this trial

Yu Wang, Dr.

86-13552647384 ywyw3172@sina.com

View on ClinicalTrials.gov More Acute Graft Versus Host Disease trials